12 research outputs found

    Efeitos da estimulação tatil-cinestésica e vestibular no recém-nascido de baixo peso e avaliação da melhor técnica: uma revisão sistemática e metanálise / Effects of tactile-kinesthetic and vestibular stimulation in low weight newborns and evaluation of best technique: a systematic review and meta-analysis

    Get PDF
    Durante anos a prematuridade tem se tornado um grande desafio dentro das Unidades de Terapia Intensiva Neonatal (UTIN), pois afeta o desenvolvimento e crescimento dos recém-nascidos (RN) decorrendo de deficiências que começariam a assumir funções normais para sua idade. A estimulação precoce tem como objetivo, devolver ao RN, seu desenvolvimento perfeito ou chegar o mais próximo da normalidade, utilizando condutas especificas, pois logo após o nascimento o cérebro apresenta uma intensa neuroplasticidade. A estimulação tátil-cinestésica proporciona ao RNPTBP, ganho de peso diário e redução do tempo de internação, pois para o recém-nascido a estimulação tátil nos seus primeiros dias de vida é maior do que qualquer outro estímulo sensorial. O objetivo do presente trabalho, foi analisar os efeitos da técnica de estimulação tátil-cinestésica com os efeitos da estimulação vestibular no recém-nascido pré-termo de baixo peso, para fazer uma comparação sobre qual será a melhor para ser aplicada no RNPTBP dentro da UTIN. Este estudo foi realizado de acordo com as recomendações dos relatórios de análises sistemáticas e metanálises (Preferred Reporting Items for Systematic Reviews and Meta- analyses PRISMA). Foram realizadas buscas nas seguintes bases de dados: LiLASC, SCOPUS, PUBMED, PEDro, MEDLINE, Web of Science; Cochrane Libary e Google Scholar. Os períodos abrangidos da pesquisa foram a partir do ano de 2.015 até o ano de 2020. Com base nas análises realizadas neste presente estudo é incontestável que a assistência à neonatos devem ser realizada de forma criteriosa e atenta as necessidades individuais de cada um, pois se essa assistência for prestada de forma inadequada, omissa, e deficiente ao recém-nascido, principalmente em condição prematura e de baixo peso, devido ao seu alto grau de vulnerabilidade, poderá acarretar sérias consequências em seu desenvolvimento que influenciará, por toda a sua vida

    Características físico-químicas e perfil de ácidos graxos de azeites obtidos de diferentes variedades de oliveiras introduzidas no Sul de Minas Gerais - Brasil

    No full text
    This work had as an objective, to analyze, both physically and chemically, five olive tree varieties  kept in the EPAMIG Germplasm Bank at the Experimental Farm, in the town of  Maria da Fé, MG. Physical characteristics of the fruits and seeds (weight, diameter and length) and some chemical characteritics of the oils extracted from five varieties (acidity, iodine, saponification, peroxide indices and the fatty acid profile) were evaluated. The Negroa variety presented an average percent of lipids (28.2%) significantly higher than the others (p < 0.05). Out of the studied varieties,  both Negroa and JB1 showed the highest yield and acidity values and the saponification, iodine and peroxide indices were more consistent with the ANVISA norms (2005) and the Codex Alimentarius (2003). All the varieties grown at Maria da Fé presented oleic acid levels within those recommended by Codex alimentarius and significantly higher than the analyzed commercial extra virgin oleic acid level (p < 0.05). The fatty acid profile found showed that all the varieties (JB1, Negroa, Ascolano 315, 0025 and 0004) have adequate values for the main groups of fatty acids, compared with the legislation. The results point out that the Negroa and JB1 varieties present better potential for use in olive oil production.Este trabalho teve por objetivo analisar, física e quimicamente, cinco variedades de oliveiras mantidas no banco de germoplasma pela EPAMIG, na Fazenda Experimental no município de Maria da Fé, MG. Foram avaliadas características físicas dos frutos e sementes (peso, diâmetro e comprimento) e algumas características químicas dos azeites extraídos de cinco variedades (índice de acidez, iodo, saponificação, peróxidos e perfil de ácidos graxos). A variedade Negroa apresentou percentual médio de lipideos (28,2%) significativamente maior que as demais (p < 0,05). Dentre as variedades estudadas a Negroa e JB1 apresentaram maior produtividade e valores de acidez, índice de saponificação, iodo e peróxidos mais compatíveis com as normas da ANVISA (2005) e o Codex Alimentarius (2003). Todas as variedades cultivadas em Maria da Fé apresentaram conteúdos de ácido oléico dentro do recomendado pelo Codex alimentarius e significativamente maior que o teor de ácido oléico do azeite comercial extra virgem analisado (p < 0,05). O perfil de ácidos graxos encontrado demonstrou que todas as variedades (JB1, Negroa, Ascolano 315, 0025 e 0004) estão com seus valores adequados para os principais grupos de ácidos graxos, quando comparados com a legislação. Os resultados indicam que das variedades analisadas a Negroa e JB1 apresentam melhor potencial para utilização na produção de azeite de oliva

    Characterisation of microbial attack on archaeological bone

    Get PDF
    As part of an EU funded project to investigate the factors influencing bone preservation in the archaeological record, more than 250 bones from 41 archaeological sites in five countries spanning four climatic regions were studied for diagenetic alteration. Sites were selected to cover a range of environmental conditions and archaeological contexts. Microscopic and physical (mercury intrusion porosimetry) analyses of these bones revealed that the majority (68%) had suffered microbial attack. Furthermore, significant differences were found between animal and human bone in both the state of preservation and the type of microbial attack present. These differences in preservation might result from differences in early taphonomy of the bones. © 2003 Elsevier Science Ltd. All rights reserved

    Respiratory support in patients with severe COVID-19 in the International Severe Acute Respiratory and Emerging Infection (ISARIC) COVID-19 study: a prospective, multinational, observational study

    No full text
    Background: Up to 30% of hospitalised patients with COVID-19 require advanced respiratory support, including high-flow nasal cannulas (HFNC), non-invasive mechanical ventilation (NIV), or invasive mechanical ventilation (IMV). We aimed to describe the clinical characteristics, outcomes and risk factors for failing non-invasive respiratory support in patients treated with severe COVID-19 during the first two years of the pandemic in high-income countries (HICs) and low middle-income countries (LMICs). Methods: This is a multinational, multicentre, prospective cohort study embedded in the ISARIC-WHO COVID-19 Clinical Characterisation Protocol. Patients with laboratory-confirmed SARS-CoV-2 infection who required hospital admission were recruited prospectively. Patients treated with HFNC, NIV, or IMV within the first 24 h of hospital admission were included in this study. Descriptive statistics, random forest, and logistic regression analyses were used to describe clinical characteristics and compare clinical outcomes among patients treated with the different types of advanced respiratory support. Results: A total of 66,565 patients were included in this study. Overall, 82.6% of patients were treated in HIC, and 40.6% were admitted to the hospital during the first pandemic wave. During the first 24 h after hospital admission, patients in HICs were more frequently treated with HFNC (48.0%), followed by NIV (38.6%) and IMV (13.4%). In contrast, patients admitted in lower- and middle-income countries (LMICs) were less frequently treated with HFNC (16.1%) and the majority received IMV (59.1%). The failure rate of non-invasive respiratory support (i.e. HFNC or NIV) was 15.5%, of which 71.2% were from HIC and 28.8% from LMIC. The variables most strongly associated with non-invasive ventilation failure, defined as progression to IMV, were high leukocyte counts at hospital admission (OR [95%CI]; 5.86 [4.83-7.10]), treatment in an LMIC (OR [95%CI]; 2.04 [1.97-2.11]), and tachypnoea at hospital admission (OR [95%CI]; 1.16 [1.14-1.18]). Patients who failed HFNC/NIV had a higher 28-day fatality ratio (OR [95%CI]; 1.27 [1.25-1.30]). Conclusions: In the present international cohort, the most frequently used advanced respiratory support was the HFNC. However, IMV was used more often in LMIC. Higher leucocyte count, tachypnoea, and treatment in LMIC were risk factors for HFNC/NIV failure. HFNC/NIV failure was related to worse clinical outcomes, such as 28-day mortality. Trial registration This is a prospective observational study; therefore, no health care interventions were applied to participants, and trial registration is not applicable

    Respiratory support in patients with severe COVID-19 in the International Severe Acute Respiratory and Emerging Infection (ISARIC) COVID-19 study: a prospective, multinational, observational study

    No full text
    Background: Up to 30% of hospitalised patients with COVID-19 require advanced respiratory support, including high-flow nasal cannulas (HFNC), non-invasive mechanical ventilation (NIV), or invasive mechanical ventilation (IMV). We aimed to describe the clinical characteristics, outcomes and risk factors for failing non-invasive respiratory support in patients treated with severe COVID-19 during the first two years of the pandemic in high-income countries (HICs) and low middle-income countries (LMICs). Methods: This is a multinational, multicentre, prospective cohort study embedded in the ISARIC-WHO COVID-19 Clinical Characterisation Protocol. Patients with laboratory-confirmed SARS-CoV-2 infection who required hospital admission were recruited prospectively. Patients treated with HFNC, NIV, or IMV within the first 24 h of hospital admission were included in this study. Descriptive statistics, random forest, and logistic regression analyses were used to describe clinical characteristics and compare clinical outcomes among patients treated with the different types of advanced respiratory support. Results: A total of 66,565 patients were included in this study. Overall, 82.6% of patients were treated in HIC, and 40.6% were admitted to the hospital during the first pandemic wave. During the first 24 h after hospital admission, patients in HICs were more frequently treated with HFNC (48.0%), followed by NIV (38.6%) and IMV (13.4%). In contrast, patients admitted in lower- and middle-income countries (LMICs) were less frequently treated with HFNC (16.1%) and the majority received IMV (59.1%). The failure rate of non-invasive respiratory support (i.e. HFNC or NIV) was 15.5%, of which 71.2% were from HIC and 28.8% from LMIC. The variables most strongly associated with non-invasive ventilation failure, defined as progression to IMV, were high leukocyte counts at hospital admission (OR [95%CI]; 5.86 [4.83–7.10]), treatment in an LMIC (OR [95%CI]; 2.04 [1.97–2.11]), and tachypnoea at hospital admission (OR [95%CI]; 1.16 [1.14–1.18]). Patients who failed HFNC/NIV had a higher 28-day fatality ratio (OR [95%CI]; 1.27 [1.25–1.30]). Conclusions: In the present international cohort, the most frequently used advanced respiratory support was the HFNC. However, IMV was used more often in LMIC. Higher leucocyte count, tachypnoea, and treatment in LMIC were risk factors for HFNC/NIV failure. HFNC/NIV failure was related to worse clinical outcomes, such as 28-day mortality. Trial registration This is a prospective observational study; therefore, no health care interventions were applied to participants, and trial registration is not applicable

    Association of Country Income Level With the Characteristics and Outcomes of Critically Ill Patients Hospitalized With Acute Kidney Injury and COVID-19

    No full text
    Introduction: Acute kidney injury (AKI) has been identified as one of the most common and significant problems in hospitalized patients with COVID-19. However, studies examining the relationship between COVID-19 and AKI in low- and low-middle income countries (LLMIC) are lacking. Given that AKI is known to carry a higher mortality rate in these countries, it is important to understand differences in this population. Methods: This prospective, observational study examines the AKI incidence and characteristics of 32,210 patients with COVID-19 from 49 countries across all income levels who were admitted to an intensive care unit during their hospital stay. Results: Among patients with COVID-19 admitted to the intensive care unit, AKI incidence was highest in patients in LLMIC, followed by patients in upper-middle income countries (UMIC) and high-income countries (HIC) (53%, 38%, and 30%, respectively), whereas dialysis rates were lowest among patients with AKI from LLMIC and highest among those from HIC (27% vs. 45%). Patients with AKI in LLMIC had the largest proportion of community-acquired AKI (CA-AKI) and highest rate of in-hospital death (79% vs. 54% in HIC and 66% in UMIC). The association between AKI, being from LLMIC and in-hospital death persisted even after adjusting for disease severity. Conclusions: AKI is a particularly devastating complication of COVID-19 among patients from poorer nations where the gaps in accessibility and quality of healthcare delivery have a major impact on patient outcomes

    Thrombotic and hemorrhagic complications of COVID-19 in adults hospitalized in high-income countries compared with those in adults hospitalized in low- and middle-income countries in an international registry

    No full text
    Background: COVID-19 has been associated with a broad range of thromboembolic, ischemic, and hemorrhagic complications (coagulopathy complications). Most studies have focused on patients with severe disease from high-income countries (HICs). Objectives: The main aims were to compare the frequency of coagulopathy complications in developing countries (low- and middle-income countries [LMICs]) with those in HICs, delineate the frequency across a range of treatment levels, and determine associations with in-hospital mortality. Methods: Adult patients enrolled in an observational, multinational registry, the International Severe Acute Respiratory and Emerging Infections COVID-19 study, between January 1, 2020, and September 15, 2021, met inclusion criteria, including admission to a hospital for laboratory-confirmed, acute COVID-19 and data on complications and survival. The advanced-treatment cohort received care, such as admission to the intensive care unit, mechanical ventilation, or inotropes or vasopressors; the basic-treatment cohort did not receive any of these interventions. Results: The study population included 495,682 patients from 52 countries, with 63% from LMICs and 85% in the basic treatment cohort. The frequency of coagulopathy complications was higher in HICs (0.76%-3.4%) than in LMICs (0.09%-1.22%). Complications were more frequent in the advanced-treatment cohort than in the basic-treatment cohort. Coagulopathy complications were associated with increased in-hospital mortality (odds ratio, 1.58; 95% CI, 1.52-1.64). The increased mortality associated with these complications was higher in LMICs (58.5%) than in HICs (35.4%). After controlling for coagulopathy complications, treatment intensity, and multiple other factors, the mortality was higher among patients in LMICs than among patients in HICs (odds ratio, 1.45; 95% CI, 1.39-1.51). Conclusion: In a large, international registry of patients hospitalized for COVID-19, coagulopathy complications were more frequent in HICs than in LMICs (developing countries). Increased mortality associated with coagulopathy complications was of a greater magnitude among patients in LMICs. Additional research is needed regarding timely diagnosis of and intervention for coagulation derangements associated with COVID-19, particularly for limited-resource settings

    Characteristics and outcomes of an international cohort of 600 000 hospitalized patients with COVID-19

    Get PDF
    Background: We describe demographic features, treatments and clinical outcomes in the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) COVID-19 cohort, one of the world's largest international, standardized data sets concerning hospitalized patients. Methods: The data set analysed includes COVID-19 patients hospitalized between January 2020 and January 2022 in 52 countries. We investigated how symptoms on admission, co-morbidities, risk factors and treatments varied by age, sex and other characteristics. We used Cox regression models to investigate associations between demographics, symptoms, co-morbidities and other factors with risk of death, admission to an intensive care unit (ICU) and invasive mechanical ventilation (IMV). Results: Data were available for 689 572 patients with laboratory-confirmed (91.1%) or clinically diagnosed (8.9%) SARS-CoV-2 infection from 52 countries. Age [adjusted hazard ratio per 10 years 1.49 (95% CI 1.48, 1.49)] and male sex [1.23 (1.21, 1.24)] were associated with a higher risk of death. Rates of admission to an ICU and use of IMV increased with age up to age 60&nbsp;years then dropped. Symptoms, co-morbidities and treatments varied by age and had varied associations with clinical outcomes. The case-fatality ratio varied by country partly due to differences in the clinical characteristics of recruited patients and was on average 21.5%. Conclusions: Age was the strongest determinant of risk of death, with a ∼30-fold difference between the oldest and youngest groups; each of the co-morbidities included was associated with up to an almost 2-fold increase in risk. Smoking and obesity were also associated with a higher risk of death.&nbsp;The size of our international database and the standardized data collection method make this study a comprehensive international description of COVID-19 clinical features. Our findings may inform strategies that involve prioritization of patients hospitalized with COVID-19 who have a higher risk of death
    corecore